Madden Securities Corp Reata Pharmaceuticals Inc Transaction History

Madden Securities Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 06, 2023	SELL	$79.22 - $105.37 $214,527 - $285,341	-2,708 Reduced 11.42%	21,000 $2.14 Million
Q3 2022 Oct 13, 2022	SELL	$19.41 - $36.49 $1,164 - $2,189	-60 Reduced 0.25%	23,708 $596,000
Q1 2022 Apr 28, 2022	SELL	$24.12 - $39.6 $374,921 - $615,542	-15,544 Reduced 39.54%	23,768 $779,000
Q4 2021 Jan 14, 2022	BUY	$25.61 - $110.96 $158,397 - $686,287	6,185 Added 18.67%	39,312 $1.04 Million
Q3 2021 Oct 14, 2021	SELL	$100.0 - $143.02 $167,500 - $239,558	-1,675 Reduced 4.81%	33,127 $3.33 Million
Q2 2021 Jul 14, 2021	BUY	$78.27 - $151.29 $1,174 - $2,269	15 Added 0.04%	34,802 $4.93 Million
Q1 2021 Apr 30, 2021	SELL	$94.25 - $132.81 $34,401 - $48,475	-365 Reduced 1.04%	34,787 $3.47 Million
Q4 2020 Jan 12, 2021	SELL	$102.03 - $184.62 $895,313 - $1.62 Million	-8,775 Reduced 19.98%	35,152 $4.35 Million
Q3 2020 Oct 08, 2020	BUY	$93.53 - $163.34 $53,779 - $93,920	575 Added 1.33%	43,927 $4.28 Million
Q2 2020 Jul 14, 2020	BUY	$126.3 - $176.56 $19,323 - $27,013	153 Added 0.35%	43,352 $6.76 Million
Q4 2019 Feb 25, 2020	BUY	$74.57 - $217.92 $3.22 Million - $9.41 Million	43,199 New	43,199 $8.83 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Madden Securities Corp, based on Form 13F filings with the SEC.

Stay updated on Madden Securities Corp with notifications on news.